Allianz Research Institute | Westminster, CA

Research site

(Unclaimed)

Location

14120 Beach Boulevard 101, Westminster, California, United States of America

Site insights

Top conditions

Top treatments

Dupilumab

Astegolimab

Bococizumab

EDP-938

RPT193

BPS-314d-MR-PAH-303

UPB-101

Verekitug

VIR-7831

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 15 total trials

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this...

Enrolling

Bronchiectasis

Drug: Placebo

Drug: Itepekimab (SAR440340)

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. (RSVHR)

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling

RSV Infection

Drug: EDP-938

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Astegolimab

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Astegolimab

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling

Severe Asthma

Drug: Placebo

Drug: Verekitug (UPB-101)

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Inhaled Long-Acting Muscarinic Antagonist

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (ATLAS)

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling

Asthma

Drug: Placebo

Drug: Dupilumab